News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Novartis Corporation (NVS) Takes Option on TRANSGENE (TRGNY) Cancer Vaccine; Transgene Gets $10 Million, Milestones Could Reach $950 Million


3/10/2010 6:46:23 AM

Reuters -- Novartis has taken an exclusive option to develop Transgene's (TRNG.PA) cancer vaccine TG4010, but the deal fell short of investors' hopes, pulling the shares in the French biotechnology company down 12 percent.



comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES